Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma

Written By Mukul Verma

Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center

Mukul Verma
Previous

Ovarian cancer survivor: Immunotherapy clinical trial saved my life
Next

Israeli biotech company begins trial for cancer immuno-oncology solution